MTM1 and X-linked myotubular myopathy: Following the fatal death of three patients in the ASPIRO clinical study (MTM1 gene therapy, see therapy section) possibly linked to liver complications, hepatobiliary disease in XLMTM was further characterized in two recent studies [24,25].